Clinical Trials Logo

Multiple Myeloma (MM) clinical trials

View clinical trials related to Multiple Myeloma (MM).

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05908409 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

CASSANDRA
Start date: June 5, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The main aims of this 2-part study are: - Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise specified (DLBCL-NOS), high-grade B cell lymphoma with double or triple hit rearrangement (HGBL-DH/TH) and HGBL-NOS, and chronic lymphocytic leukemia (CLL). - Phase II: To evaluate the overall response rate (ORR), duration of response (DoR), time to progression (TTP), progression-free survival (PFS), event-free survival (EFS) and Overall survival (OS), in patients with MM, DLBCL-NOS, HGBL-DH/TH, HGBL-NOS or CLL treated with IDP-121 at the recommended Phase 2 Dose (RP2D).

NCT ID: NCT05442580 Recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

CART-38 in Adult AML and MM Patients

Start date: May 30, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label Phase 1 study to estimate the safety and manufacturing feasibility of lentivirally transduced T cells expressing anti-CD38 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in patients with Acute Myeloid Leukemia and Multiple Myeloma. This CAR T cell product will be referred to as "CART-38 cells".

NCT ID: NCT04649073 Recruiting - Clinical trials for Multiple Myeloma (MM)

Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma

Start date: February 18, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the tolerability,safety and efficacy of OPC-415 in patients with relapsed and/or refractory Multiple Myeloma (MM).

NCT ID: NCT03018405 Recruiting - Clinical trials for Multiple Myeloma (MM)

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

THINK
Start date: December 2016
Phase: Phase 1/Phase 2
Study type: Interventional

THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells in seven refractory cancers, including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma).